Αποτελέσματα Αναζήτησης
1 Οκτ 2021 · The AE management cost for FOLFIRINOX and the utility value for PD played a vital role in model outcomes. When AE costs for FOLFIRINOX varied from $43,270 to $52,886, the ICER changed from $202,400 to $256,426, which was still higher than the WTP threshold of $200,000 for this model.
8 Ιουν 2022 · Using this comprehensive clinical data set from 1102 patients with mPC across multiple regions and health care systems in the US, we explored survival outcomes, posttreatment hospitalizations, and treatment costs associated with FOLFIRINOX and gemcitabine plus nab-paclitaxel regimens.
19 Δεκ 2018 · Adjuvant therapy with a modified FOLFIRINOX regimen led to significantly longer survival than gemcitabine among patients with resected pancreatic cancer, at the expense of a higher...
The total costs of FOLFIRINOX regimen in our sample was 273465,50€, with 4143,41€average cost per patient. About 68% patients had hospital admission during treatment, with 12 average days of stay and 2000€of cost.
A four-drug chemotherapy regimen has produced the longest improvement in survival ever seen in a phase III clinical trial of patients with metastatic pancreatic cancer, one of the deadliest types of cancer. Patients who received the regimen, called FOLFIRINOX, lived approximately 4 months longer than patients treated with the current standard ...
17 Μαΐ 2012 · The costs per QALYs for FOLFIRINOX were about $45,000 to $55,000. Thus, even though the component drugs of the FOLFIRINOX regimen cost more than single-agent gemcitabine, FOLFIRINOX is more cost-effective than gemcitabine. FOLFIRINOX has therefore received a favorable funding recommendation in most Canadian provinces.
FOLFIRINOX (FFX) was introduced to clinical practice in 2010 following publication of the PRODIGE 4/ACCORD 11 study, which compared this novel regimen to gemcitabine in metastatic pancreatic cancer. Median overall survival, progression-free survival, and objective responses were all superior with FFX and there was improved time to definitive ...
